Betty Pang advises clients in the healthcare and life sciences industry on regulatory matters and corporate transactions.

Dr. Pang brings a comprehensive view of the industry to advise clients on complex and sensitive issues pertaining to:

  • Fraud and abuse
  • Self-referral and government program reimbursement compliance
  • Facility and provider licensing
  • Corporate practice and fee-splitting

She represents a full spectrum of clients in the healthcare ecosystem, including:

  • Hospitals and health systems
  • Physician practice management companies and affiliated practices
  • Clinical laboratory and diagnostic service providers
  • Telehealth, digital health and wellness companies
  • Life science companies, including pharmaceutical, medical device, biotechnology, and medical suppliers
  • Private equity firms
  • Investment banks

With a seasoned understanding of the industry drawn from prolific deal flow, and a complementary understanding of the scientific and medical issues drawn from her medical degree, she efficiently and effectively support clients through:

  • Mergers and acquisitions
  • Initial public offerings
  • Financings
  • Joint ventures
  • Government investigations
  • Day-to-day regulatory and compliance issues

Dr. Pang has focused her entire career on the healthcare and life sciences industry, and is a member of the American Health Lawyers Association, the California Society for Healthcare Attorneys, and the American Bar Association Health Law Section. She serves as a Bay Area Local Office Leader for Latham’s Asian and Middle Eastern Lawyers Group and has served as an advisor for the firm’s Diversity Scholars Program.

Regulatory clients include:

  • Ceribell
  • Cerula Care
  • Eargo
  • Eleusis
  • Elevar Therapeutics
  • Galen Healthcare
  • Health Outlook
  • Healthy Longevity Clinic
  • Inari
  • Neuralink
  • Oscar Health
  • P3 Health Partners
  • Perry Health
  • Praxis Precision Medicines
  • RIPPL Care
  • Tenet
  • The Cooper Companies
  • The Oncology Institute

Ms. Pang’s transactional work includes:

Capital Markets

  • Aimmune Therapeutics in its US$160 million initial public offering
  • Aligos Therapeutics in its US$173 million initial public offering
  • Angion Biomedical in its US$117 million initial public offering
  • Arcutis Biotherapeutics in its US$183 million common stock offering
  • Ascendis Pharma in its US$500 million initial public offering and subsequent US$500 million convertible notes offering
  • Corvus Pharmaceuticals in its US$60 million follow-on offering
  • CytomX Therapeutics in its US$116.9 million initial public offering and follow-on offering
  • Gritstone Oncology in its US$74.8 million offering
  • Imago BioSciences in its US$134.4 million initial public offering
  • Oscar Health in its US$1.44 billion initial public offering
  • Prometheus Biosciences in its US$218 million initial public offering
  • Prothena in its US$72.6 million offering
  • Revolution Medicines in its:
    • US$230 million public offering
    • US$300 million common stock offering
  • Rhythm Pharmaceuticals in its US$172 million common stock offering
  • Sana Biotechnology in its US$675 initial public offering
  • Teladoc in its US$180 million initial public offering
  • Numerous underwriters in various offerings, including:
    • Aclaris Therapeutics’ US$25 million at-the-market offering
    • Alpine Immune Sciences' US$100 million public offering
    • Aspira Women’s Health’s US$52 million common stock offering
    • Chinook Therapeutics’ US$105 million public offeringEliem Therapeutics’ initial public offering
    • Halozyme Therapeutics’ US$700 million convertible senior notes offering
    • Instil Bio’s US$320 million initial public offering
    • Minerva Surgical’s US$75 million initial public offering
    • Petco’s US$279 initial public offering
    • Sientra’s US$42 million common stock offering
    • Vor Biopharma’s US$203 million initial public offering

Mergers and Acquisitions

  • Bonti in its US$195 million sale to Allergan
  • CooperCompanies in its acquisition of Cook Medical’s Reproductive Health business
  • Eleusis in its US$446 million business combination with Silver Spike Acquisition Corp.
  • IIImago BioSciences in its pending US$1.35 billion acquisition by Merck
  • Khosla Ventures Acquisition Co. in its US$2.25 billion business combination with Valo Health
  • KKR in its:
    • US$1.4 billion acquisition of PharMerica
    • US$354 million acquisition of Covenant Surgical Partners
  • Leonard Green & Partners L.P. in its US$363 million acquisition of Prospect Medical Holdings
  • North American Science Associates (NAMSA) in its US$43.5 million acquisition of American Preclinical Services, LLC
  • Pionyr Immunotherapeutics in its US$275 million sale to Gilead Sciences
  • Preventice Solutions in its US$1.23 billion sale to Boston Scientific


  • Bank of America and Merrill Lynch, Fenner, Pierce & Smith in the US$3 billion term loan and revolving credit facilities in connection with Gilead Science’s US$11.2 billion acquisition of Pharmasset, a clinical stage pharmaceutical company focused primarily on developing oral therapeutics for the treatment of hepatitis C
  • Deutsche Bank in the incremental term loan and revolving credit facility in connection with Endo Limited's acquisition of Par Pharmaceutical Holdings, a specialty pharmaceutical company
  • Innocoll Biotherapeutics in its US$125 million term loan provided by funds managed by Oaktree Capital
  • JPMorgan in the:
    • US$3.65 billion term loan and revolving credit facility for PPD, a global contract research organization that provides drug discovery, clinical development, lifecycle management, and laboratory services, to refinance existing debt
    • US$38.3 billion term loan facilities in connection with Takeda Pharmaceutical Company Limited’s acquisition of Shire plc, an Ireland-based biopharmaceutical company
  • SLR Capital Partners in the US$300 million debt facilities for Outset Medical

Bar Qualification

  • California


  • MD, Stanford University, 2005
  • JD, Harvard Law School, 2003
  • BA, Stanford University, 1998
  • BS, Stanford University, 1998